Literature DB >> 18074366

Medication adherence and associated outcomes in medicare health maintenance organization-enrolled older adults with Parkinson's disease.

Amit S Kulkarni1, Rajesh Balkrishnan, Roger T Anderson, Heather M Edin, Jeff Kirsch, Mark A Stacy.   

Abstract

Maintenance of symptom control in Parkinson's disease (PD) requires continuous titration of medication and addition of multiple therapies over the course of the disease. Adherence to medication is vital to symptom control and key to maximizing the efficacy of existing therapies. However, adherence is compromised by a variety of factors, including motor symptoms, complex dosing regimens, multiple medications, and lack of patient/physician awareness of the impact and prevalence of suboptimal adherence. This retrospective, longitudinal cohort study assessed the prevalence of suboptimal adherence [measured as the medication possession ratio (MPR)] to PD medications, and its impact on the worsening of PD symptoms (measured as increase in monotherapy dose, augmentation of therapy, PD-related emergency department visit, or hospitalization), in a Medicare Health Maintenance Organization population in the United States. Irrespective of the MPR threshold chosen, a high percentage of patients were categorized as suboptimally adherent to their PD medications, and patients with suboptimal adherence to their PD medications had higher risks of worsening of PD symptoms, compared with those who were adherent. Increased awareness of both the magnitude and impact of suboptimal adherence to PD medications, coupled with dosage simplification and a unified effort by healthcare professionals and patients, may improve adherence to PD medications and ultimately improve symptom control. 2007 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18074366     DOI: 10.1002/mds.21831

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  29 in total

1.  Economic evaluation of ropinirole prolonged release for treatment of Parkinson's disease in the Netherlands.

Authors:  Job F M van Boven; Annoesjka Novak; Maurice T Driessen; Cornelis Boersma; Maarten M Boomsma; Maarten J Postma
Journal:  Drugs Aging       Date:  2014-03       Impact factor: 3.923

Review 2.  Medication nonadherence in Parkinson's disease.

Authors:  Jori E Fleisher; Matthew B Stern
Journal:  Curr Neurol Neurosci Rep       Date:  2013-10       Impact factor: 5.081

Review 3.  Medication (re)fill adherence measures derived from pharmacy claims data in older Americans: a review of the literature.

Authors:  Elisabeth Lilian Pia Sattler; Jung Sun Lee; Matthew Perri
Journal:  Drugs Aging       Date:  2013-06       Impact factor: 3.923

4.  Instrumental activities of daily living performance among people with Parkinson's disease without dementia.

Authors:  Erin R Foster
Journal:  Am J Occup Ther       Date:  2014 May-Jun

5.  Associations and implications of low health literacy in Parkinson's Disease.

Authors:  Jori E Fleisher; Krunal Shah; Whitney Fitts; Nabila A Dahodwala
Journal:  Mov Disord Clin Pract       Date:  2015-12-14

6.  The association between medication non-adherence and adverse health outcomes in ageing populations: A systematic review and meta-analysis.

Authors:  Caroline A Walsh; Caitriona Cahir; Sarah Tecklenborg; Catherine Byrne; Michael A Culbertson; Kathleen E Bennett
Journal:  Br J Clin Pharmacol       Date:  2019-09-06       Impact factor: 4.335

7.  The association between adherence to levodopa/carbidopa/entacapone therapy and healthcare utilization and costs among patients with Parkinson's disease: a retrospective claims-based analysis.

Authors:  Thomas E Delea; Simu K Thomas; May Hagiwara
Journal:  CNS Drugs       Date:  2011-01       Impact factor: 5.749

Review 8.  Medication adherence in patients with Parkinson's disease.

Authors:  Naveed Malek; Donald G Grosset
Journal:  CNS Drugs       Date:  2015-01       Impact factor: 5.749

9.  Development and Validation of the Parkinson's Disease Medication Beliefs Scale (PD-Rx).

Authors:  Jori E Fleisher; Nabila A Dahodwala; Sharon X Xie; Mark Mayo; Daniel Weintraub; Joshua Chodosh; Judy A Shea
Journal:  J Parkinsons Dis       Date:  2016-04-02       Impact factor: 5.568

10.  Adherence to anti-Parkinson drug therapy in the "REASON" sample of Italian patients with Parkinson's disease: the linguistic validation of the Italian version of the "Morisky Medical Adherence Scale-8 items".

Authors:  G Fabbrini; G Abbruzzese; P Barone; A Antonini; M Tinazzi; G Castegnaro; S Rizzoli; D E Morisky; P Lessi; R Ceravolo
Journal:  Neurol Sci       Date:  2013-06-01       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.